Healthcare

Popular Topics in Healthcare

Subscribe to Updates in Healthcare

By RSS

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

GLG News by Oncologists who Treat Hematologic Malignancies (US)

Articles with lock require a subscription to GLG News |

Request a free trial

June 30, 2008

How are we to pay for computers with a 10% drop in Medicare fees?
Analysis of: Medicare fees to doctors fall Tuesday | news.yahoo.com
Author: GLG Expert Contributor

Rising costs for care of seniors in physician offices will be made more painful by the reimbursement cuts. Will it impede care of seniors??

June 27, 2008

The other shoe falls II: Amgen and J & J will not be happy.
Analysis of: Europe Backs Anemia-Drug Warnings | online.wsj.com
Author: GLG Expert Contributor

Due to possible tumor growth warnings will be attached to the use of erythropoietin agents.

June 26, 2008

Bayer and J &J in the propylactic anticoagulation market. GSK (Lovenox) beware!
Analysis of: Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty | content.nejm.org
Author: GLG Expert Contributor

This paper as well as http://content.nejm.org/cgi/content/full/358/26/2765 report the efficacy of an oral anticoagulant type drug that appears to be better & safer than parenteral low molecular weight heparin (LMWH).

June 23, 2008

Amgen as well as J & J: Adding insult to injury......
Analysis of: New Study Probes Safety of Erythropoiesis-Stimulating Agents | www.medscape.com
Author: GLG Expert Contributor

Safety concerns continue to be voiced re: the effect of erythropoietin products (Epos) on tumor growth.

June 20, 2008

Electronic Records?? Great but.......
Analysis of: Most Doctors Aren’t Using Electronic Health Records | www.nytimes.com
Author: GLG Expert Contributor

Only 1 in 5 physicians use electronic patient records. ( and those are either in University Hospitals, large multispecialty clinics or VA hospitals)

June 19, 2008

GSK is going after Genentech's (Herceptin) Cookies....
Analysis of: Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer | jco.ascopubs.org
Author: GLG Expert Contributor

Lapatinib, an oral HER-2 inhibitor, is effective in monotherapy in HER-2+ metastatic breast cancer.

June 19, 2008

Melanoma: The Holy Grail at Last??
Analysis of: Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1 | content.nejm.org
Author: GLG Expert Contributor

"In summary, THEY showed that the infusion of a clonal population of CD4+ T cells with specificity for a single tumor-associated antigen caused complete regression of a tumor. During regression of the tumor, this clone appears to have induced the patient's own T cells to respond to other antigens of...

June 11, 2008

Targeted therapy for myeloproliferative disorders (MPD) from Cephalon
Analysis of: Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor

Very preliminary but this agent may offer a targeted, more "natural" approach to the MPD's- Polycythemia Vera, Myelofibrosis and Primary thrombocytosis.

June 9, 2008

Transgene's vaccine for SCLC: Promising, BUT need to await survival and Phase III data
Analysis of: Transgene's Therapeutic Vaccine TG4010 Meets Primary Endpoint in Non-Small Cell Lung Cancer Phase IIb Trial | www.pipelinereview.com
Author: GLG Expert Contributor

Tarnsgene's cancer vaccine TG 4010 increased response rates and progression free survival when added to chemotherapy in patients with advanced small cell lung cancer. The overall survival rates and time to progression were not much different in the 2 treatment groups. The vaccine is novel and efficacy...

June 9, 2008

Diabetes: Let's avoid pseudoscience and start over.....
Analysis of: Tight Rein on Blood Sugar Has No Heart Benefit | www.nytimes.com
Author: GLG Expert Contributor

Tight Glucose control in type 2 diabetes mellitus did not result in improved survival and possibly had a negative impact.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next41 to 50 of 728

More GLG News in
Healthcare

GLG News: What Experts Think Is Important

Generated at 2008-09-07T01:45:17.680

GLG News by Oncologists who Treat Hematologic Malignancies (US)

More GLG News inHealthcare

GLG News: What Experts Think Is Important

More GLG News in
Healthcare